Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alclometasone Dipropionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 8/20 | 1.00 |
| ▸ | USP2 | O75604 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | CNR1 | P21554 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alclometasone Dipropionate SCHEMBL13985345 | 1.00 | PGR (1.00) | PGRUSP2NR3C1CYP3A4HIF1A | |
| Alclometasone Dipropionate SCHEMBL6833 | 1.00 | PGR (1.00) | PGRUSP2NR3C1CYP3A4HIF1A | |
| Alclometasone Dipropionate SCHEMBL11047317 | 1.00 | PGR (1.00) | PGRUSP2NR3C1CYP3A4HIF1A | |
| Alclometasone Dipropionate SCHEMBL13423590 | 1.00 | PGR (1.00) | PGRUSP2NR3C1CYP3A4HIF1A | |
| SCHEMBL13653198 | 0.92 | PGR (0.86) | PGRUSP2NR3C1CYP3A4HIF1A | |
| SCHEMBL36537 | 0.92 | NR3C1 (0.85) | PGRUSP2NR3C1CYP3A4HIF1A | |
| SCHEMBL11584194 | 0.92 | USP2 (0.85) | PGRUSP2NR3C1CYP3A4HIF1A | |
| SCHEMBL11584722 | 0.92 | NR3C1 (0.85) | PGRUSP2NR3C1CYP3A4HIF1A | |
| SCHEMBL14339625 | 0.92 | NR3C1 (0.85) | PGRUSP2NR3C1CYP3A4HIF1A | |
| SCHEMBL11584724 | 0.92 | NR3C1 (0.85) | PGRUSP2NR3C1CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178579-B1 | 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZINEDIONE AS GLUCOCORTICOID-SPARING AGENT | METRIOPHARM AG (CH) | 2025-02-12 | — | — | EP | claimed |
| CN-118141602-A | Lacrimal canaliculus embolism | 上海曙瑞科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-117310043-A | Analysis method for rapidly screening various illegal additives in toner | 中山海关技术中心 | 2023-12-29 | — | — | CN | claimed |
| CN-116348093-A | Pharmaceutical composition of intra-articular corticosteroid for pain control | TLC生物医药公司 | 2023-06-27 | — | — | CN | claimed |
| CN-115087431-A | Pressurized metered dose inhalers comprising buffered pharmaceutical formulations | 奇斯药制品公司 | 2022-09-20 | — | — | CN | claimed |
| CN-115003282-A | Pressurized metered dose inhalers comprising buffered pharmaceutical formulations | 奇斯药制品公司 | 2022-09-02 | — | — | CN | claimed |
| CN-122031378-A | Preparation of phosphoramidate derivatives of nucleoside drugs | 努卡那有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12564598-B2 | Nitric oxide-sensitive hydrogel | POSTECH Research and Business Development Foundation (KR) | 2026-03-03 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025227057-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING IMMUNE-RELATED ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITOR TREATMENT | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4616192-A1 | METHODS OF PREDICTING AND TREATING IMMUNOTHERAPY TOXICITY BASED ON IMMUNE CELL POPULATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4581011-A1 | NOVEL SELECTIVE INHIBITORS OF LYSYL OXIDASES | Syntara Limited (AU) | 2025-07-09 | — | — | EP | disclosed |
| CN-114555624-A | Anti-inflammatory agents | 悉尼大学 | 2022-05-27 | — | — | CN | disclosed |
| US-11311598-B2 | Peptides and analogs for use in the treatment of oral mucositis | SOLIGENIX, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| CN-114395624-A | Methods for treatment and diagnosis of cancer | 基因泰克公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-110461407-B | Drug infusion component and system | 美敦力泌力美公司 | 2022-04-15 | — | — | CN | disclosed |
| CN-114126574-A | External preparation for skin | 花王株式会社 | 2022-03-01 | — | — | CN | disclosed |
| CN-107690429-B | Composition for the treatment and/or prevention of necrosis of cells or tissue, specifically targeting cathepsin C and/or CELA1 and/or CELA3A and/or enzymes structurally related thereto | ELA制药有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20220054467-A1 | TREATMENT OF PSORIASIS WITH TOPICAL TAPINAROF-TAZAROTENE COMBINATION COMPOSITIONS | SOL-GEL TECHNOLOGIES LTD. (IL) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311598-B2 | Peptides and analogs for use in the treatment of oral mucositis | IFNAR1, DCLRE1A, VIP | NR3C1 2526/4885PGR 3810/4885USP2 1382/4885 |
| US-12564598-B2 | Nitric oxide-sensitive hydrogel | NOS1, NOS2, NOS3 | NR3C1 766/4885PGR 1784/4885USP2 534/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | NR3C1 4364/4885PGR 157/4885USP2 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.